Dendritic Cells and Their Role in Immunotherapy.

Gardner A, de Mingo Pulido Á, Ruffell B. · 2020

Read Dendritic Cells and Their Role in Immunotherapy. by Gardner A, de Mingo Pulido Á, Ruffell B. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7253577.txt.

Introduction

Gardner and co-authors review dendritic cells and their place in cancer immunotherapy. Their review appeared in Frontiers in Immunology. Dendritic cells start immune responses by showing antigens, small identifying pieces of a threat, to T cells. That role made them an early focus for cancer vaccines, though results were often weak.

New tools have revived interest. Immune checkpoint blockade and the ability to spot patient-specific neoantigens allow new vaccine designs and combination treatments. Dendritic cells inside tumors also shape how well other therapies work. The authors sort the main dendritic cell subsets, explain how each steers the anti-tumor response, and review the current state of dendritic cell therapies to point out where trials should go next.

Catalog record

CREATORGardner A, de Mingo Pulido Á, Ruffell B.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE78 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7253577

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Dendritic Cells and Their Role in Immunotherapy By Alycia Gardner, Álvaro de Mingo Pulido, Brian Ruffell Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2020.00924 ABSTRACT Despite significant advances in the field of cancer immunotherapy, the majority of patients still do not benefit from treatment and must rely on traditional therapies. Dendritic cells have long been a focus of cancer immunotherapy due to their role in inducing protective adaptive immunity, but cancer vaccines have shown limited efficacy in the past. With the advent of immune checkpoint blockade and the ability to identify patient-specific neoantigens, new vaccines, and combinatorial therapies are being evaluated in the clinic. Dendritic cells are also emerging as critical regulators of the immune response within tumors. Understanding how to augment the function of these intratumoral dendritic cells could offer new approaches to enhance immunotherapy, in addition to improving the cytotoxic and targeted therapies that are partially dependent upon a robust immune response for their efficacy. Here we will discuss the role of specific dendritic cell subsets in regulating the anti-tumor immune response, as well as the current status of dendritic cell-based immunotherapies, in order to provide an overview for future lines of research and clinical trials. INTRODUCTION Immunotherapy has revolutionized the treatment of many solid and hematological malignancies, with immune checkpoint blockade (ICB), adoptive cell therapy (ACT) using tumor infiltrating leukocytes (TIL), and vaccine strategies targeting different aspects of the immune-oncology cycle to improve the functionality of T lymphocytes. Each of these strategies, however, is necessarily predicated on the initiation of the cycle, namely the presentation of tumor antigens by professional antigen-presenting cells (APCs) (1). APCs can be defined by their ability to capture, process, and present exogenous antigen to T cells, and are usually identified by their constitutive expression of major histocompatibility complex (MHC) II and costimulatory molecules. Thus, dendritic cells (DCs), macrophages, and B cells are normally considered to be the three major populations of APCs. It should be noted that other populations also constitutively express MHCII, including thymic epithelial cells, while still others can acquire exogenous antigen, and express MHCII following activation, including eosinophils and basophils (2, 3). However, in the context of solid tumors, antigen uptake, and presentation are primarily the domain of macrophages and DCs (4). While macrophages are the dominant phagocytic population in tumors, they do not migrate to the lymph nodes and are unable to activate T cells ex vivo (4). Instead, macrophages are usually found to blunt T cell responses against tumors via multiple mechanisms and act to suppress therapeutic response to ICB as well as chemotherapy and irradiation (5, 6). DCs thus have a unique ability to transport tumor antigen to the draining lymph nodes to initiate T cell activation, a process that is required for T cell-dependent immunity and response to ICB (4, 7–10). Tumor-resident DCs also have an emerging role in regulating the T cell response within tumors during therapy (4, 11–14). These functions place DCs at the fulcrum of the anti-tumor T cell response and suggest that regulating the biological activity of these cells is a viable therapeutic approach to indirectly promote a T cell response during therapy. DENDRITIC CELLS IN CANCER DCs are the quintessential APCs of the immune system, responsible for bridging the gap between innate and adaptive immunity, including the activation of anti-tumor T cells (4, 7–10). DCs arise from bone marrow progenitors known as common myeloid progenitors (CMPs). From here, two cell subtypes diverge. Expression of the transcription factor Nur77 drives the differentiation of CMPs into monocytes, which can further differentiate into monocyte DCs (moDCs) under inflammatory conditions (15–18). In the absence of Nur77, CMPs differentiate into the common dendritic cell progenitor (CDP), which gives rise both to plasmacytoid DCs (pDCs) and conventional DCs (cDCs) (15). Differentiated cDCs are initially immature, requiring maturation signals (for instance, damage or pathogen associated molecular patterns [DAMPs or PAMPs], or inflammatory cytokines) to fully effect their role in the immune response (15, 18). Upon maturation and activation, DCs downregulate phagocytosis, increase MHC and costimulatory molecule expression, increase cytokine production, and display enhanced migration to lymph nodes, likely driven by higher expression of C-C chemokine receptor 7 (CCR7) (15). As a result of the phenotypic changes that occur during activation, mature DCs are able to prime naïve T cells and initiate the adaptive immune response. cDCs can be further divided into two subsets, known as type one (cDC1) and type two (cDC2) conventional DCs. cDC1 are defined by reliance on the transcription factors BATF3 and IRF8 for development, and express several common surface markers across species, including XCR1, CLEC9A, CADM1, BTLA, and CD26 (19). However, the cells were originally identified by surface expression of CD8α (lymphoid organ resident) or CD103 (peripheral tissue resident) in mice (20–22) and CD141 (BDCA-3) in humans (23–25), making these the most commonly used markers. In both organisms, the cDC1 subset displays enhanced ability to cross-present exogenous antigen and activate CD8+ T cells (15, 18, 26), but this functional demarcation between the cDC1 and cDC2 subset is more pronounced in mice than in humans (19). In both mice and humans cDC1s represent a small percentage of immune cells in circulation. cDC1 accounted for <0.01% of CD45+ cells in the blood of healthy human donors, as well as <0.1% of CD45+ cells in surveyed tissue sites (27). cDC2 are easiest to identify by the absence of cDC1 markers, but higher expression of CD11b, CD1c, and SIRPα (CD172α) is also frequently used to distinguish the population, with IRF4 acting as the key transcription factor (28–31). No specific markers identify migratory from resident cDC2 populations in mice, but differential expression of CD11c and MHCII can be used as a distinguishing feature (15). In mice, cDC2 are primarily responsible for presentation of endogenous antigen to CD4+ T cells and shaping the resulting polarization of the cells, with the ability to polarize CD4+ T cells also observed with human cDC2 (32). As mentioned, however, human cDC2s can cross-present antigen and produce high levels of interleukin (IL)12, properties that are largely restricted to the cDC1 subset in mice (19). Thus, despite the critical role of cDC1s in the development and maintenance of anti-tumor immunity in experimental models (15), it is possible cDC2s have an unidentified role in human cancers. Indeed, a recent study demonstrated a correlation between cDC2 abundance and non-Treg CD4+ T cell infiltration into head and neck squamous carcinomas. High cDC2 and low Treg infiltration was also associated with longer progression-free survival (33). Type 1 Conventional DCs In mice, cDC1 are responsible for the induction of the “cancer-immune cycle,” as Batf3-deficient mice are unable to reject even highly immunogenic tumors or respond to immune-mediated therapies such as checkpoint blockade and adoptive T cell transfer (7–10, 13, 34). This has been traced to the ability of cDC1s to transport antigen from tumors into draining lymph nodes, with migratory cDC1s being the only APC subset capable of causing robust activation and proliferation of CD8+ T cells ex vivo (9, 10). Additionally, migratory cDC1 represented the only cDC subset able to transport antigen to the lymph node in two studies using melanoma models (9, 10). cDC trafficking to the lymph node and generation of a systemic anti-tumor immune response is governed

Read the complete text